Anzeige
Meldung des Tages: Diese Aktie zündet die nächste Explorationsstufe – und der Markt beginnt aufzuwachen.

Icecure Medical News

Aktie
WKN:  A1W1LG ISIN:  IL0011224156 US-Symbol:  ICCM Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Israel
0,3536 $
-0,0085 $
-2,35%
0,3011 € 21.04.26
Depot/Watchlist
Marktkapitalisierung *
34,19 Mio. €
Streubesitz
52,20%
KGV
-
Index-Zuordnung
-

Icecure Medical News

21.04.26 - PR Newswire
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 PR ...
26.03.26 - PR Newswire
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
25.03.26 - PR Newswire
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-​Free Rates PR Newswire
24.03.26 - PR Newswire
IceCure Appoints Meir Peleg as Chief Financial Officer
IceCure Appoints Meir Peleg as Chief Financial Officer PR Newswire
17.03.26 - PR Newswire
IceCure Reports 2025 Full Year Financial & Operational Results
IceCure Reports 2025 Full Year Financial & Operational Results PR Newswire
11.03.26 - PR Newswire
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
U.S. FDA Approves IceCure's Post-​Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer PR Newswire
10.03.26 - PR Newswire
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 PR Newswire
09.03.26 - PR Newswire
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer PR Newswire
02.03.26 - PR Newswire
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas PR Newswire
23.02.26 - PR Newswire
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 PR Newswire
19.02.26 - PR Newswire
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation PR Newswire
11.02.26 - PR Newswire
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® PR Newswire
09.02.26 - PR Newswire
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved PR Newswire
28.01.26 - PR Newswire
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer PR ...
12.01.26 - PR Newswire
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales PR Newswire
17.12.25 - PR Newswire
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer PR Newswire
10.12.25 - PR Newswire
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting PR Newswire
05.12.25 - PR Newswire
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PR Newswire
19.11.25 - PR Newswire
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PR Newswire
18.11.25 - PR Newswire
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer PR Newswire

Newssuche

Videos

newspaper
20.04.26 +1,65%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »